Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We're excited about the key near-term data catalysts, which we believe will present the opportunity to propel Ironwood's growth and create value for patients and shareholders for years to come |
| But we are pleased with the uptake and pleased with the return on investment |
| I'm absolutely delighted to share with you the progress we made in 2023 and why we believe our future is bright |
| We're going to learn a lot from the study in terms of how to model that pharmacodynamic response, but it certainly is part of the PK/PD profile that we think is very positive and aspirational for Apraglutide |
| I am very proud of the Ironwood team and the significant headway we made in 2023 across our three strategic priorities, which are: maximize LINZESS, advance our GI pipeline and deliver sustained profits and cash flows |
| As we turn our attention to 2024, I'm confident in our strategy and look forward to what we expect to be an exciting and transformational year for our company |
| and the key pipeline catalysts ahead of us, which we believe can propel Ironwood's next phase of growth |
| In its 11th year on the market, LINZESS had another terrific year as the leading prescription treatment for adults with IBS-C and chronic idiopathic constipation |
| In 2023, prescription demand increased a robust 10% year-over-year |
| We are excited about the continued strong LINZESS performance |
| In addition, LINZESS reached an all-time high of 46% in TRx share in the combined branded and generic IBS-C and chronic idiopathic constipation market strengthening its market leadership |
| net sales were $1.73 billion, an increase of 7% year-over-year, driven by continued strong LINZESS prescription demand growth of 10% |
| Moving forward, our focus remains on continuing to grow LINZESS subscription demand and delivering strong brand profits and cash flow |
| And just from a new to brand, specific dose size that 92-microgram or so microgram dose, we feel really -- we feel positive about it |
| Last year, we strengthened our GI pipeline with the acquisition of VectivBio, including its lead asset, Apraglutide as the next-generation, long-acting GLP-2 analog, we believe Apraglutide, if successful, has the potential to become the standard of care in treating patients with short bowel syndrome dependent on parenteral support based on its clinical profile and the potential convenient once-weekly dosing |
| I'm pleased that we were able to meet or exceed all three of our guidance metrics in 2023 |
| Apraglutide's unique pharmacologic properties and strong clinical data to date, including the positive data from the STARS Nutrition study gives us confidence in the STARS Phase 3 study which will let on track to read out in March |
| Again, it's pretty impressive in my mind |
| We believe the strong demand momentum and success of LINZESS will continue as a result of high treatment satisfaction with both patients and health care professionals, combined with increased clinical utility from the new pediatric syndication, class-leading formulary access, guideline recommendations, focused commercial execution and new patient start acceleration |
| We believe both Apraglutide and CNP-104 have the potential to improve standard of care and the quality of life for patients suffering from these serious GI diseases with key data expected this year |
| And that's one of the reasons why we think that once weekly has the potential opportunity to best-in-class |
| As you can see, demand growth has been remarkable over time, reinforcing that patients and health care professionals continue to choose LINZESS in a growing market |
| Looking ahead to 2024, we expect to deliver greater than $150 million in adjusted EBITDA, while continuing to progress multiple clinical programs with the potential to deliver long-term growth |
| We believe the positive momentum across the pipeline programs, combined with the continued strong performance of LINZESS uniquely positions us for success of our mission to be the leader in GI |
| So, I think it increases the intention and the momentum in this marketplace and hopefully, if we're right, we can really take advantage |
| As Tom mentioned earlier, LINZESS had another very strong year in 2023 |
| And in June of 2023, LINZESS received FDA approval for the functional constipation in pediatric patients ages six to 17, becoming the first and only approved prescription therapy for this patient population, an achievement we're incredibly proud of |
| The near-term catalysts I just highlighted reinforce our confidence in the tremendous opportunity we have in front of us with multiple programs that we believe have the potential to improve the standard of care and the quality of life for patients suffering with GI diseases |
| We're excited about CNP-104 because it has the potential to be the first disease-modifying therapy for patients suffering with PBC |
| We believe Apraglutide, if successful and approved has best-in-class potential as the only once-weekly GLP-2 analog for the whole spectrum of patients with short bowel syndrome dependent on parenteral support also known as SBS-IF, a disease for which there is considerable unmet need |
| Statement |
|---|
| So, it's poor within our strategy |
| Adjusted EBITDA was $40 million in Q4 and a loss of $885 million for the full year |
| But for this year, we do think that there will be a meaningful headwind from a price perspective just given our volumes on Medicaid |
| And today, we think the price erosion and any other fluctuations will essentially be mid to high single-digit headwind to have low single-digit growth in for the full year |
| Now if some of those headwinds do not materialize, we could have a year that resembles last year |
| GAAP net loss was $2 million in the fourth quarter |
| Is the assumed pediatric growth driving some increased Medicaid exposure that actually makes that erosion a little bit worse |
| The full year adjusted EBITDA loss also includes the onetime charge of approximately $1.1 billion from the acquisition of VectivBio |
| It's something that we just want to be more cautious about from a guidance perspective |
| Maybe talk about the different moving pieces that could drive outperformance or underperformance on that guide from a standpoint of the net pricing decline assumptions |
Please consider a small donation if you think this website provides you with relevant information